Sydney-based molecular biologist Dr Noelle Sunstrom has won the inaugural Women in Export Scholarship.
Dr Sunstrom is the founder and CEO of NeuClone Pty Ltd, which develops and commercialises high quality biosimilar medical products.
NeuClone’s patented technology enhances the production of biologic drugs by causing cells to increase protein expression, creating cost-efficiencies for manufacturers. This has led to a partnership with the Serum Institute of India, the world’s largest vaccine maker.
Trade Minister Steven Ciobo said NeuClone is a perfect example of how Australian innovation is generating global interest and creating Australian jobs.
“NeuClone’s disruptive technologies will deliver a significant social impact and Dr Sunstrom, as the inventor, founder and CEO of NeuClone, is a very worthy recipient of this scholarship,” Mr Ciobo said.
Dr Sunstrom, who is originally from Canada, obtained a PhD from McGill University in Montreal before moving to Australia on a post-doctoral scholarship with the John Curtin School of Medical Research at the Australian National University.
Collaborating with big pharma
She began her academic research career at the University of NSW, where she led a team in producing monoclonal antibody drug therapies for the influenza virus, collaborating with big pharma in taking those drugs to market. She and her team developed cutting-edge ways to produce complex biopharmaceuticals for commercial production.
In 2000, Dr Sunstrom co-founded Acyte Biotech, which commercialises intellectual property from the mammalian cell research groups at the University of NSW and University of QLD.
She completed an Executive MBA in 2007 and soon after founded NeuClone. Sunstrom is also a Fellow of the Australian Institute of Company Directors and the Royal Society of NSW.
The Women in Export Scholarship is offered in partnership by Austrade and Chief Executive Women (CEW).
Dr Sunstrom will attend Harvard Business School’s Disruptive Innovation – Strategies for a Successful Enterprise program, delivered at Boston, Massachusetts next month.